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Abstract
Several studies indicate that mitochondrial ATP production as well as ADP/ATP exchange across mitochondrial membranes are impaired
during apoptosis. We investigated whether Bcl-2 could protect against cell death under conditions in which ATP metabolism is inhibited.
Inhibition of ATP production using antimycin A (AA) (complex III inhibition) combined with inhibition of ADP/ATP exchange by
bongkrekic acid (BA) (adenine nucleotide translocator (ANT) inhibition) induced a sharp decrease in total cellular ATP in FL5.12 parental
cells (to 35% of untreated controls after 24 h of incubation). Within 24 and 48 h, 38% and 75% of the cells had died, respectively. However,
in stably transfected FL5.12 Bcl-2 subclones, no cell death occurred under these experimental conditions. Similar results were obtained with
Jurkat and Bcl-2 overexpressing Jurkat cells. Total cellular ATP levels were equally affected in FL5.12 Bcl-2 overexpressing cells and FL5.12
parental cells. This indicates that Bcl-2 overexpressing cells are able to survive with very low cellular ATP content. Furthermore, Bcl-2 did
not protect against cell death by restoring ATP levels. This suggests that, under these conditions, Bcl-2 acts by inhibiting the signalling
cascade triggered by the inhibitors that would normally lead to apoptosis. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
In recent years, scientific interest in mitochondria has
received a new impulse by the discovery that these energy-
providing organelles also play a vital role in cell death
processes. Trapped between the outer and inner membrane,
mitochondria harbour proteins that, once released, initiate a
cascade of proteolytic activity in the cytosol and nucleus,
thus causing apoptotic cellular degradation.
One of the main factors released by mitochondria during
apoptosis is cytochrome c [1]. In the cytosol, cytochrome c
associates with Apaf-1 and procaspase-9 to form a complex
called the apoptosome. In this complex, procaspase-9 is
cleaved into its active form and in turn caspase-3, an
important effector caspase, becomes proteolytically acti-
vated [2–4]. Other apoptogenic factors harboured in the
mitochondrial intermembrane space include apoptosis
inducing factor (AIF), second mitochondria-derived activa-
tor of caspase (SMAC), and procaspases-2, -3 and-9 [5–9].
Thus far, it is not clear whether the release of these factors
occurs through specific transport or by means of physical
disruption of the outer mitochondrial membrane. The events
leading to outer mitochondrial membrane permeabilisation
also remain unclear [10].
A number of changes occur in mitochondria early during
apoptosis. In many different systems apoptosis is accom-
panied by a marked decrease in mitochondrial membrane
potential. It has been suggested that this decrease represents
the opening of a pore complex (permeability transition pore;
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PT pore) in mitochondrial membranes [11]. Opening of the
PT pore is thought to cause osmotic swelling of the
mitochondrial matrix and subsequent rupture of the outer
mitochondrial membrane, thus releasing apoptogenic fac-
tors. It has indeed been shown that many agents interfering
with the PT pore complex also have an effect on apoptotic
cell death, e.g. inhibitors of the adenine nucleotide trans-
locator (ANT) like atractyloside and bongkrekic acid (BA)
(reviewed in Ref. [12]).
Furthermore, mitochondrial energy metabolism is altered
during apoptosis. A drop in the ATP level has been as-
sociated with apoptotic cell death [13,14]. ATP decrease
may be caused by a disruption of electron transport, as has
been shown to occur during apoptosis induced by different
stimuli [15,16]. These perturbations of mitochondrial func-
tion could affect outer membrane permeability by altering
ion homeostasis causing osmotic volume dysregulation [17]
or by favouring PT [11]. Loss of cytochrome c from
mitochondria may also cause a (further) collapse of mito-
chondrial energy metabolism due to impairment of electron
transport. On the other hand, it seems that the cellular ATP
level can determine the shape of cell death upon a death
stimulus. Higher ATP levels will allow apoptosis to take
place, whereas under ATP-depleting conditions cell death is
likely to occur through necrosis [18–20].
Transport of metabolites, e.g. adenine nucleotides, across
mitochondrial membranes is of vital importance for the
communication between mitochondrial ATP production
and cytosolic energy demand. The ANT in the inner
mitochondrial membrane and the voltage-dependent anion
channel (VDAC) in the outer mitochondrial membrane
regulate adenine nucleotide translocation and are also
implicated to play a role in apoptosis. Both the ANT and
VDAC are key components of the PT pore and could thus
be involved in apoptosis regulation [11,21,22]. Moreover,
VDAC may affect outer membrane permeability independ-
ently of its involvement in the PT pore, by forming a
nonphysiological channel large enough to allow the diffu-
sion of cytochrome c [23].
Bcl-2 family proteins are important regulators of apop-
tosis at the mitochondrial level (reviewed in Ref. [24]). A
number of Bcl-2 homologs have been shown to be localised
to the outer mitochondrial membrane and appear to affect
apoptotic mitochondrial features like the loss of mitochon-
drial membrane potential, oxidative stress and release of
cytochrome c [11]. However, the exact mechanism by which
Bcl-2 homologous proteins interfere with mitochondria to
modulate apoptosis remains to be elucidated.
Both Bcl-2 and Bax have been shown to interfere with
oxidative phosphorylation [25,26] in apoptosis. Bcl-2
homologous proteins are thought to interfere with mitochon-
drial membrane permeability in several ways. Bcl-2, Bcl-xL,
Bax and Bak can bind to and thereby regulate both the ANT
[27,28] and the VDAC [23], and may thus enhance or
diminish mitochondrial permeability through the PT pore
[29]. Pro-apoptotic Bax may also promote or take part in the
formation of a cytochrome c-permeant VDAC pore [23,30],
whereas anti-apoptotic Bcl-xL is thought to prevent apop-
tosis by allowing VDAC to maintain its normal open state
[31,32]. In addition, Bcl-2 family proteins could form
autonomous channels in mitochondrial membranes [33–
35], which may allow the translocation of proteins [36,37]
or affect mitochondrial ion homeostasis and thus influence
mitochondrial permeability [38,39].
In this paper, we set out to investigate how mitochon-
drial respiration and ADP/ATP translocation are involved in
cell death and whether Bcl-2 regulates apoptosis at these
levels. To block mitochondrial respiration, we used anti-
mycin A (AA), which inhibits complex III of the electron
transport chain. Cells were treated with BA to block ade-
nine nucleotide translocation by the ANT. Our data show
that Bcl-2 protects against cell death induced by simulta-
neous inhibition of these mitochondrial functions. We
suggest that Bcl-2 acts by inhibiting the apoptotic signalling
cascade triggered by the inhibitors and does not directly
interfere with mitochondrial metabolism to maintain cellular
ATP levels.
2. Materials and methods
2.1. Cell lines and culture
The IL3-dependent murine prolymphoid cell line FL5.12
(FL5.12 parental) and its derivative FL5.12 Bcl-2 were
cultured in Iscove’s modified Dulbecco’s medium (IMDM;
Life Technologies, The Netherlands) supplemented with
10% fetal calf serum, 10% Wehi-3B conditioned medium
as a source of IL3 and 50 AM b-mercaptoethanol. FL5.12
Bcl-2 was obtained by stable transfection of FL5.12 with a
vector containing human Bcl-2 and hygromycin resistance
[40]. Jurkat cell lines transfected with an empty control
vector with neomycin resistance or the same vector con-
taining human Bcl-2 were kindly provided by Dr. J. Reed
(The Burnham Institute, La Jolla, CA, USA) [41]. Jurkat
cells were cultured in IMDM supplemented with 10% fetal
calf serum and 1 AM b-mercaptoethanol.
The experiments with BA, AA, myxothiazol and stigma-
tellin were performed using Dulbecco’s modified Eagle
medium (DMEM; Life Technologies) supplemented with
4.5 g/l glucose, 2 mM sodium pyruvate, 10% fetal calf
serum, 10% Wehi-3B supernatant for FL5.12 cells and 50 or
1 AM h-mercaptoethanol for FL5.12 and Jurkat cells,
respectively. Glucose-free conditions were obtained by
washing and culturing cells in the same medium without
glucose.
In these experiments cells were cultured at 0.5 106
cells/ml and treated with 50 AM BA (kind gift of Dr. J.A.
Duine, Delft University of Technology, Delft, The Nether-
lands), 5 nM myxothiazol (Sigma-Aldrich, The Nether-
lands) or 5 nM stigmatellin (Sigma-Aldrich). FL5.12 cells
were treated with 0.5 Ag/ml AA, and for Jurkat cells 10 ng/
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ml AA was used (Sigma-Aldrich). These concentrations
were determined to be the minimal concentrations needed
to induce massive cell death by AA in the absence of
glucose (data not shown).
2.2. Western blot analysis
Cell pellets were resuspended in lysis buffer containing
142.5 mM KCl, 5 mM MgCl 2, 10 mM Hepes pH= 7.3, 1
mM EGTA, 1% Triton X-100, 0.5% Nonidet-P40 and
freshly added protease inhibitors (0.3 AM aprotinin, 0.3
AM pepstatin A, 10 AM leupeptin and 0.2 mM phenyl-
methylsulphonyl fluoride) and kept on ice for 45 min.
Proteins were separated by gel-electrophoresis on 14%
pre-cast tris–glycine gels (Novex, San Diego, CA, USA)
and transferred to polyvinylidene difluoride membranes.
Bcl-2 was stained using an anti-human Bcl-2 monoclonal
antibody (clone 124, Dako Diagnostics, UK).
2.3. PCR and sequence analysis of Bcl-2 constructs
RNA was extracted from cells using RNAzol (Campro
Scientific, The Netherlands) and chloroform, followed by
precipitation in isopropanol. A reverse transcriptase reaction
generated cDNA, which was used in a PCR (GC-rich PCR
system; Roche Diagnostics, Indianapolis, IN, USA) with
primers specific for human Bcl-2 (forward primer: 5V-
CAGAAGCTTCCGTTGCTTTTCCTCTGGGA-3V; reverse
primers: 5V-TCACTTGTGGCCCAGATAGG-3V and 5V-
CATGGTACATCACTGACAATGCATAT-3V, for FL5.12
and Jurkat, respectively). After gel electrophoresis, PCR
products of expected length were visible and the human Bcl-
2 nucleotide sequence was verified by automated fluores-
cent sequencing (3700 ABI Prism, Perkin-Elmer Biosys-
tems, Foster City, CA, USA).
2.4. Flowcytometric analysis of cell death and early-stage
apoptosis
Cell death was determined by staining cells with propi-
dium iodide (10 Ag/ml, PI) at 20 jC for 15 min. Samples
were analysed on a Coulter Epics Elite flow cytometer
(Beckman-Coulter, Miami, FL, USA) equipped with a 40-
mW Argon laser running at 15 mW. A minimum of 5000
cells per sample was analysed in duplicate. To measure red
fluorescence (PI) we used a high-pass filter of 610 nm.
Table 1
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Fig. 1. Overexpression of Bcl-2 in FL5.12 and Jurkat cell lines. Lysates of
FL5.12 parental cells (lane 1), FL5.12 cells transfected with human Bcl-2
(FL5.12 Bcl-2; lane 2), Jurkat cells transfected with a control vector (Jurkat-
neo; lane 3) and Jurkat cells transfected with human Bcl-2 (Jurkat-Bcl-2;
lane 4) were separated and blotted on a PVDF filter. Bcl-2 protein was
detected using a specific Bcl-2 monoclonal antibody.
Fig. 2. AA and BA do not induce cell death in FL5.12 and Jurkat cells as
single agents. (A) FL5.12 parental cells and (B) Jurkat-neo cells were
treated with AA (0.5 Ag/ml and 10 ng/ml, respectively, white columns),
which inhibits complex III of the mitochondrial respiratory chain, to assess
whether inhibition of mitochondrial ATP production affects cell death. The
effects of inhibition of ADP/ATP exchange on cell death were determined
by treating cells with BA (50 AM), which blocks the ANT (gray columns).
Cells were treated with AA in absence of glucose, which blocks glycolysis
in the cytosol (black columns). Cell death was determined by flowcyto-
metric analysis of propidium iodide staining.
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To measure early-stage apoptosis, cells were incubated at
20 jC for 15 min in the presence of 1.2 Ag/ml annexinV/
FITC (Bender Medsystems, Vienna, Austria) [42], 1.6 Ag/ml
PI and 2.5 mM CaCl2. Cells were subsequently analysed on
the flow cytometer using a 525-nm band-pass filter for the
FITC-signal and a 610-nm high-pass filter for PI.
2.5. DNA fragmentation
Cells (5 106) were washed in 0.9% NaCl and sub-
sequently lysed in ice-cold lysis buffer (142.5 mM KCl, 5
mM MgCl2, 10 mM HEPES pH 7.3, 1 mM EGTA, 1%
Triton X-100, 0.5% Nonidet-P40, with freshly added pro-
tease inhibitors; 2.7 AM aprotinin, 0.3 AM pepstatin A, 10
AM leupeptin and 0.2 mM phenylmethylsulfonyl fluoride
(PMSF)) for 45 min. Cellular debris were spun down and
DNA was isolated from the supernatant by phenol extrac-
tion.
The DNA samples were subsequently analysed by gel
electrophoresis on a 1.2% E-gel (Invitrogen, The Nether-
lands) to screen for the presence of a DNA ladder pattern
(DNA fragments of approximately 200 bp and multitudes of
200 bp).
2.6. Measurement of cellular ATP content
Adenine nucleotides were extracted from samples of
5 106 viable cells in 0.4 M perchloric acid on ice for 10
min. The supernatant was neutralized with 0.1% (v/v) 4.0 M
K2HPO4 and subsequently stored at  80 jC.
ATP, ADP and AMP contents of the samples were
determined using an automated HPLC system (Waters
Corporation, Millford, MA, USA), equipped with a 996
photodiode array detector, a 600S controller, a 717 auto-
sampler, a 626 HPLC-pump and a partisil SAX 10 u HPLC
column (250 4.6 mm, Alltech, Deerfield, IL, USA). The
UV detector was set at 254 nm. The operating pressure was
1150 psi and the flow-rate was 1.3 ml/min. A three-buffer
system was used for separation (Table 1; buffer A: 50 mM
KH2PO4, 0.03% (v/v) CH3CN, 1 mg/l sodium azide, pH
3.25; buffer B: 0.03% (v/v) acetonitril, 1 mg/l sodium azide;
buffer C: 0.5 M KH2PO4, 0.015% (v/v) acetonitril, 1 mg/l
sodium azide, pH 5.25).
Per sample, 100 Al of supernatant was injected into the
HPLC system. A standard curve was generated from seven
samples with a concentration range of ATP, ADP and AMP,
from which the concentration of adenine nucleotides present
in the test samples could be determined.
Automatic data capture and processing were performed
using Millenium 32 software (version 3.05.01, Waters).
Duplicate samples were measured and ATP, ADP concen-
Fig. 3. Combined inhibition of respiratory chain complex III and ADP/ATP
exchange induces cell death in FL5.12 parental cells, but not in Bcl-2-
overexpressing cells. (A) FL5.12 parental (closed squares) and FL5.12 Bcl-
2 cells (open circles) were treated with complex III inhibitor AA (0.5 Ag/ml)
in combination with BA (50 AM) and subsequently cell death was
determined by propidium staining on a flowcytometer. (B) FL5.12 cells
were treated with complex III inhibitor myxothiazol (5 nM) in combination
with BA and analysed for cell death. (C) FL5.12 cells were treated with
complex III inhibitor stigmatellin (5 nM) in combination with BA and cell
death was analysed.
Fig. 4. The combination of AA and BA induces cell death in Jurkat-neo
cells, but not in Bcl-2-overexpressing cells. Jurkat-neo (closed squares) and
Jurkat-Bcl-2 cells (open circles) were treated with AA (10 ng/ml) combined
with BA (50 AM) and, subsequently, cell death was determined by flow
cytometric analysis of propidium iodide staining.
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trations are given in picomoles per 106 cells (AMP data not
shown).
3. Results
3.1. Overexpression of Bcl-2 in FL5.12 and Jurkat cell lines
Overexpression of Bcl-2 in the transfected FL5.12 and
Jurkat cells was determined by Western blot analysis. In
FL5.12 cells, no endogenous Bcl-2 could be detected,
whereas Jurkat cells expressed a small amount of endogenous
Bcl-2 (Fig. 1, lanes 1 and 3). Lanes 2 and 4 of Fig. 1 clearly
show the increased expression of the Bcl-2 protein in the Bcl-
2-transfected derivatives of FL5.12 and Jurkat. With PCRs
using primers specific for human Bcl-2, the nucleotide
sequence of transfected Bcl-2 was verified. We thus excluded
the possibility that mutations were introduced during the
selection procedure and concluded that the Bcl-2 protein
overexpressed in our cells was identical to wild-type Bcl-2.
Fig. 5. Apoptotic features of cell death induced by the combination of AA and BA in FL5.12 and Jurkat cells. (A) FL5.12 parental cells, Jurkat-neo cells and
Bcl-2 overexpressing subclones were treated with AA (0.5 Ag/ml for FL5.12 and 10 ng/ml for Jurkat) together with BA (50 AM) and were subsequently
analysed for the presence of a ladder of bands in the DNA, indicating endonucleosomal DNA degradation. Lanes 1–3: FL5.12 parental cells after 0, 24 and 48
h of treatment, respectively. Lanes 4–6: FL5.12 Bcl-2 cells after 0, 24 and 48 h of treatment, respectively. Lanes 7–9: Jurkat-neo cells after 0, 24, 48 h of
treatment. Lanes 10–12: Jurkat-Bcl-2 cells after 0, 24, 48 h of treatment. (B) Jurkat-neo and Jurkat-Bcl-2 cells were treated with AA (10 ng/ml) in combination
with BA (50 AM) for 0, 6, 12, 24, 30 and 48 h and were subsequently stained with annexinV/FITC and propidium iodide (PI) and analysed on a flow cytometer.
AnnexinV-positive (loss of plasma membrane asymmetry) and PI-negative staining (plasma membrane integrity) (Ann+/PI ) marks early stage apoptosis and
percentages of cells with these features are given in the lower right quadrants. Cells undergoing apoptosis in vitro will subsequently become Ann+/PI+, when
they lose plasma membrane integrity and become late-apoptotic/secondary necrotic (percentages in upper right quadrants).
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3.2. Inhibition of mitochondrial respiration or ADP/ATP
exchange does not induce cell death
Because of the involvement of mitochondrial res-
piration and ADP/ATP exchange in cell death, we set
out to investigate whether inhibition of these functions
affects viability of FL5.12 and mock-transfected Jurkat
cells.
When mitochondrial ATP production was inhibited by
AA at the level of complex III of the electron transport
chain, FL5.12 cells survived normally and no cell death
was induced (Fig. 2A). Inhibition of ADP/ATP exchange
through the ANT by BA did not cause cell death in
FL5.12 cells either. Similar results were obtained using
Jurkat(-neo) cells (Fig. 2B). When glycolytic ATP produc-
tion was prevented simultaneously with inhibition of mito-
chondrial respiration (treatment with AA in absence of
glucose) or ADP/ATP exchange (treatment with BA in
absence of glucose), cell death was induced in both
FL5.12 and Jurkat cells (Fig. 2A and B and data not
shown).
3.3. Bcl-2 protects against apoptosis induced by combined
inhibition of mitochondrial respiration and ADP/ATP ex-
change
Since no effects on cell viability could be found when
using single mitochondrial inhibitors, subsequently, the
effect of the combination of AA and BA was investigated.
Contrary to the findings of treatment with the single
inhibitors, combined treatment induced cell death in
FL5.12 parental and Jurkat cells (Figs. 3A and 4). Remark-
ably, in Bcl-2 overexpressing FL5.12 (two independently
derived subclones; one of which is shown in Fig. 3A) and
Jurkat cells, the combination of AA and BA did not induce
cell death.
The experiments were also performed with other inhib-
itors of electron transport at complex III, myxothiazol and
stigmatellin. Similar to AA, myxothiazol and stigmatellin in
combination with BA induced cell death in FL5.12 parental
cells, but not in FL5.12 Bcl-2 cells (Fig. 3B and C).
Analysis of DNA from the FL5.12 parental and Jurkat
cells treated with AA and BA clearly showed the appear-
Fig. 6. ATP levels do not explain the cell death phenomena caused by AA in combination with BA. To assess the effects of the combination of AA and BA on
cellular ATP levels, the ATP content in extracts from 5 106 viable cells was determined by HPLC. (A) FL5.12 parental cells and (B) FL5.12 Bcl-2 cells were
treated with AA (0.5 Ag/ml) and BA (50 AM). Subsequently, the ATP content was measured in cell extracts after 6 and 24 h of incubation and was calculated in
picomoles per 106 cells, as a mean of duplicate samples (untreated controls: dashed lines, open squares; AA/GF-treated cells: solid lines, open circles; AA/BA-
treated cells: solid lines, closed squares). (C, D) Relative ATP levels of FL5.12 parental (black columns) and FL5.12 Bcl-2 cells (gray columns) are calculated
as percentages of ATP content of untreated controls. The ATP content of untreated controls is fixed at 100% and represented by a black line. (C) Relative ATP
levels of FL5.12 cells after treatment with AA under GF conditions, to block simultaneously mitochondrial and glycolytic ATP production and thus induce
cellular ATP depletion. (D) Relative ATP levels of FL5.12 cells after combined AA and BA treatment.
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ance of DNA laddering (Fig. 5A), which is associated with
apoptotic DNA degradation. DNA laddering could not be
detected in Bcl-2 overexpressing FL5.12 and Jurkat cells
after similar treatment. Flow cytometry analysis of cells
stained with annexin V/propidium iodide showed that early
apoptosis (characterised by an increased percentage of
annexinV positive, PI negative cells) occurred in Jurkat-
neo cells treated simultaneously with AA and BA (Fig. 5B).
In Jurkat-Bcl-2 these changes occurred in less than 15% of
the cells, when treated with this combination.
3.4. Combined inhibition of mitochondrial respiration and
ADP/ATP exchange results in ATP depletion irrespective of
Bcl-2 overexpression
Both AA and BA are inhibitors that interfere with ATP
metabolism, either in the production or transport of ATP. To
investigate whether the cell death phenomena that were
found with the combination of these inhibitors could be
explained by their effect on ATP, the ATP content of FL5.12
cells was analysed with timepoints at 6 and 24 h of treat-
ment with AA in combination with BA (Fig. 6A and B). The
amount of ATP found in untreated FL5.12 parental cells was
slightly lower than the amount found in untreated FL5.12
Bcl-2 cells (824 vs. 1082 pmol/106 cells), and this amount
increased during the course of the experiment in both cell
types. This increase in basal ATP content has been reported
before [43] and seemed to be correlated to continued growth
and increased cell number.
Treatment with AA and BA caused a decrease in the ATP
level in FL5.12 parental cells, and even more prominently in
FL5.12 Bcl-2 cells (Fig. 6A and B). As a control for total
cellular ATP depletion, we also treated FL5.12 parental and
Bcl-2 cells with AA under glucose-free (GF) conditions to
block both mitochondrial and glycolytic ATP production.
Under these conditions, virtually all cells die within 48 h
(Fig. 2A) and Bcl-2 can no longer protect against cell death
(data not shown). The amount of ATP is rapidly decreased
when cells are treated with AA under GF conditions (Fig.
6A and B). Calculated as a percentage of the amount of ATP
found in untreated cells, the decrease in ATP is to approx-
imately 45% after 6 h, down to less than 25% after 24 h
(Fig. 6C). After treatment with the combination of AA and
BA, a similar decrease is seen in FL5.12 Bcl-2 cells (Fig.
6D; about 55% after 6 h and 25% after 24 h) and to a lesser
extent in FL5.12 parental cells (about 75% after 6 h and
35% after 24 h). We also examined whether Bcl-2 may act
to preserve the ATP/ADP ratio under these circumstances
which may have a low ATP+ADP pool (Table 2). However,
we found that the ATP +ADP pool was not remarkably low
and there was a decrease in ATP/ADP ratio in both FL5.12
parental and FL5.12 Bcl-2 cells.
4. Discussion
In a number of studies, it has been reported that apoptotic
cell death is associated with respiratory dysfunction
[13,15,16]. Whether respiratory dysfunction is a factor that
contributes to the initiation of apoptosis or rather a conse-
quence of apoptotic changes in mitochondria, in particular
cytochrome c release, is still open for investigation. It was
shown that addition of exogenous cytochrome c can restore
impaired respiratory function early in apoptosis [44]. Others
have shown that respiratory-chain-deficient cells are predis-
posed to undergo apoptosis in vivo [45]. In our experiments,
inhibition of mitochondrial respiration at complex III of the
electron transport chain by AA does not affect viability,
indicating that impaired respiratory function does not nec-
essarily lead to cell death. Blocking ADP/ATP exchange
across the mitochondrial membrane by the ANT-inhibitor
BA does not induce cell death either, showing that a func-
tional ANT is not required for survival. Furthermore, these
data indicate that both FL5.12 and Jurkat cells can survive
under conditions where mitochondrially generated ATP is
not available in the cytosol. Under these circumstances,
glycolysis in the cytosol may provide the ATP necessary to
maintain cellular viability. This is corroborated by the
observation that cell death is induced when cells are treated
with either AA or BA in the absence of glucose. These data
furthermore show that the inhibitors are effective.
Despite the fact that the inhibitors alone had no effect on
cellular viability, we found that simultaneous inhibition of
mitochondrial respiration and adenine translocation (by
Table 2
ATP, ADP concentrations and ATP/ADP ratio of FL5.12 cells treated with AA and BA








FL5.12 parental untr. 6 h 823.6F 102.2 644.5F 74.3 1.28 1468.0
24 h 1192.5F 31.7 1234.9F 12.9 0.97 2427.4
AA/BA 6 h 650.1F 31.8 688.2F 1.5 0.94 1338.3
24 h 413.1F12.1 884.0F 30.3 0.47 1297.0
FL5.12 Bcl-2 untr. 6 h 1082.0F 18.3 865.9F 5.2 1.25 1947.9
24 h 1818.8F 15.4 1756.6F 37.6 1.04 3575.4
AA/BA 6 h 602.1F15.9 953.5F 35.6 0.63 1555.6
24 h 435.4F 20.1 1134.2F 52.0 0.38 1569.6
untr.: untreated.
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combined treatment with AA and BA) did induce cell death.
This phenomenon occurred in both murine FL5.12 and
human Jurkat cells, indicating that the effect was not
restricted to a specific cell line or species.
Since both AA and BA affect ATP metabolism (either
mitochondrial production or transport), a possible explan-
ation of their cell death-inducing capacity, when combined,
may be found in their effect on the cellular ATP content. We
indeed found a marked decrease in cellular ATP level in
FL5.12 cells treated simultaneously with AA and BA.
Massive cell death was also induced when cells were
depleted of cellular ATP by AA under GF conditions, which
blocked both mitochondrial and glycolytic ATP production.
However, ATP depletion also occurred in FL5.12 Bcl-2 cells
that were treated with AA in combination with BA, but
these cells survived the treatment. This means that ATP
depletion is not necessarily correlated with cell death and
may therefore not be the trigger of cell death induced by this
combination of inhibitors. Alternatively, ATP depletion
could trigger the induction of apoptosis, but Bcl-2 may halt
the cell death process at a level downstream of mitochon-
drial ATP metabolism.
Cell death induced by AA in combination with BA
appeared to occur through apoptosis, as the cells exhibited
endonucleosomal DNA degradation (DNA laddering) and
loss of plasma membrane asymmetry (annexinV-staining in
cells with an intact cell membrane). Severe cellular ATP
depletion is usually linked with necrotic cell death
[20,46,47]. This discrepancy may arise from the different
inhibitors used to induce ATP depletion or the dynamics of
induction. The ATP decrease in our experiments may have
been slow, reaching depletion levels only after 24 h. There-
fore, the initial amount of cellular ATP may have been
enough to meet the energy requirements for the apoptotic
death process.
As Bcl-2 inhibited cell death induced by AA combined
with BA, but did not prevent the associated decline in ATP,
Bcl-2 protection cannot be attributed to maintaining cellular
ATP levels. In addition, we found that Bcl-2 could not
rescue the ATP/ADP ratio under these conditions. Similar
results with Bcl-2 offering protection under ATP-depleting
conditions have been reported recently [48]. The failure of
Bcl-2 to prevent ATP depletion furthermore shows that Bcl-
2 is not likely to function by inducing ATP generating
mechanisms. These data are in accordance with findings in
another IL3-dependent cell line, where regulation of apop-
tosis by Bcl-2 is shown not to depend on induction of
oxidative phosphorylation or glycolysis [43].
Cells overexpressing Bcl-2 survived, despite severe cel-
lular ATP depletion. Bcl-2 may achieve this by facilitating
prolonged metabolic arrest, in which cells survive in an
energetically quiescent state and are less dependent on ATP.
This was also suggested for another IL3-dependent cell line
in which impaired metabolical function was related to cell
death [43]. However, when both mitochondrial and glyco-
lytic ATP production were blocked (by treatment with AA
under GF conditions) ATP depletion was also induced, but
Bcl-2 no longer protected against cell death. This combina-
tion of inhibitors may not allow for the establishment of a
quiescent state. The kinetics of ATP depletion induced by
blocking both mitochondrial and glycolytic ATP production
may direct cells towards cell death by necrosis instead of
apoptosis in which Bcl-2 may be prevented to exert its
inhibitory effect. It would be worthwhile to investigate
whether Bcl-2 may have an effect on mitochondrial ATP
level or mitochondrial ATP/ADP ratio. Since the total
cellular ATP level is dominated by cytosolic ATP, a possible
modulation of subcellular ATP concentrations by Bcl-2
would be easily missed.
The inhibitors used in our experiments may have other
effects besides interfering with ATP generation or traffick-
ing, which could contribute to the observed cell death
phenomena. AA has been shown to interact with Bcl-2
and Bcl-xL by mimicking a BH3-domain [49]. However, we
found similar results when cells were treated with other
complex III inhibitors (stigmatellin and myxothiazol)
instead of AA. Although it is presently not known whether
these agents could also mimic a BH3-domain, they interact
with another site than AA (Qo-site vs. Qi-site of the bc1-
complex) on complex III of the electron transport chain
[50,51]. This suggests that the cell death-inducing capacity
of AA, when combined with BA, is due to its inhibitory
effect on complex III of the respiratory chain and not caused
by other effects of AA. Apart from inhibiting ADP/ATP
exchange, BA is considered to prevent PT pore opening,
thus preventing cell death [12,17,21]. Our experiments,
however, showed that BAwas capable of inducing apoptosis
when combined with AA. As PT pore opening is not likely
to occur in the presence of BA, we suggest that another
mechanism is responsible for triggering apoptosis under
these circumstances.
Many different mechanisms have been proposed for the
anti-apoptotic effects of Bcl-2. Recent studies suggest that
Bcl-2 family proteins may regulate outer mitochondrial
membrane permeability by interaction with the VDAC
[23,30,32] or by their intrinsic pore-forming capacities
[25,35,37]. In our experiments, we directly interfered with
inner membrane permeability by inhibiting the ANT. As the
ANT and VDAC are functionally linked in complexes
localised in contact sites between the inner and outer
mitochondrial membranes, interference of the ANT with
BA may also affect VDAC and thus outer membrane
permeability [52]. Further investigations should reveal
whether this mechanism is involved in triggering apoptosis
induced by simultaneous inhibition of ADP/ATP exchange
and mitochondrial respiration and whether this is the level
on which Bcl-2 family proteins function.
In conclusion, this article provides new clues on the role
of mitochondrial function in apoptosis. Although cellular
ATP content may be affected when apoptosis is induced, our
data indicate that Bcl-2 does not protect by restoring cellular
ATP levels. We suggest that Bcl-2 prevents the effects of
A.O. de Graaf et al. / Biochimica et Biophysica Acta 1554 (2002) 57–6564
impaired mitochondrial function on permeabilization of the
outer mitochondrial membrane. Future research aiming to
unravel the exact mechanisms by which Bcl-2 homologous
proteins regulate mitochondrial permeability, should further
increase our understanding of the apoptotic cell death
process.
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